• Industrial experience: 3 years 6 months
• Teaching experience: 2 years 6 months
• Research experience: 2 years

• Multistep synthesis, purification, characterization and process development for molecules of medicinal interests .
• Computational biology, Computational Chemistry and Machine learning.
• Bioequivalence study.
• Analytical instruments Liquid chromatography-Mass Spectroscopy.

• A total > 12 years of research experience in drug research and development after M.Pharm.
• Have published 15 original research/review articles and 3 book chapters in international reputed scientific publications.
• Citation Index  (H-index = 9, i-10 index = 8).
• Direct Senior Research Fellowship granted by Council for Scientific and Industrial Research (CSIR) New Delhi on 1st April 2011 for a period of four years to carry research work on "Design and synthesis of novel Factor Xa inhibitors: The next generation antithrombotics."
• Successfully qualified GATE-2006 with all India rank of 71 and a GATE score of 539 conducted by IIT Kharagpur.
• Research guidance to M.Pharma students during PhD tenure.

• Efficiency of Homology Modeling assisted Molecular Docking in G-protein coupled receptors. Shome S. Bhunia, A.K. Saxena Current Topics in Medicinal Chemistry, 2020. Accepted (IF = 3.218)
• Design, synthesis and biological evaluation of new substituted 5-benzylideno-2-adamantylthiazol [3, 2-b][1, 2, 4] triazol-6 (5H) ones. Pharmacophore models for antifungal activity. A. Paparisva, A. Geronikaki, ChKamoutsis, A. Ćirić, J. Glamočlija, M. Soković, ChFotakis, P. Zoumpoulakis, Shome S. Bhunia, A.K. Saxena. Arabian Journal of Chemistry, 2018, 11, 573-590.(IF = 4.762)
• Molecular modelling studies in explaining the higher GPVI antagonistic activity of the racemic 2-(4-methoxyphenylsulfonyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-  carbo- xamide than its enantiomers Shome S. Bhunia, A.K. Saxena. SAR and QSAR in Environmental Research, 2017, 28, 783-799. (IF = 2.053)
• Novel glycoprotein VI antagonists as anti-thrombotics: synthesis, biological evaluation and molecular modeling studies on 2, 3-disubstituted tetrahydropyrido (3, 4-b) indoles. Shome S. Bhunia, A. Misra, I.A. Khan, S. Gaur, M. Jain, S. Singh, A. Saxena, T. Hohlfield, M. Dikshit, A.K. Saxena , Journal of Medicinal Chemistry, 2016, 60, 322-337. (IF = 6.205)
• Modelling inhibition of avian aromatase by azole pesticides. A.K. Saxena, J. Devillers, Shome S. Bhunia, E. Bro, SAR and QSAR in Environmental Research, 2015, 26, 757-782. (IF = 2.053)
• Molecular modelling studies on 2-substituted octahydropyrazinopyridoindoles for histamine H2 receptor antagonism. M. Saxena, Shome S. Bhunia, A.K. Saxena, SAR and QSAR in Environmental Research, 2015, 26, 739-755. (IF = 2.053)
• Pharmacophore Modeling, Docking and Molecular Dynamics Studies on Caspase-3 Activators Binding at β-tubulin Site. Shome S. Bhunia, S. Singh, S. Saxena, A.K. Saxena. Current computer-aided drug design, 2015, 11, 72-83. (IF = 0.953)
• Pharmacokinetics, dose proportionality and permeability of S002-333 and its enantiomers, a potent antithrombotic agent, in rabbits. A. Saxena, G.R. Valicherla, P. Joshi, R. Saxena, S. H. Cheruvu, Shome S. Bhunia, G.K. Jain, H.H. Siddiqui, A.K. Saxena, J.R. Gayen. Xenobiotica ,2015,45,1016-1023. (IF = 2.199)
• Novel Glycoconjugate of 8‐Fluoro Norfloxacin Derivatives as Gentamicin‐resistant Staphylococcus aureus Inhibitors: Synthesis and Molecular Modelling Studies. C.S. Azad, Shome S. Bhunia, A. Krishna, P.K. Shukla, A.K. Saxena. Chemical biology & drug design. 2015, 86, 440-446. (IF = 2.548)
• 4-Thiazolidinone derivatives as potent antimicrobial agents: microwave-assisted synthesis, biological evaluation and docking studies. E. Pitta, E. Tsolaki, A. Geronikaki, J. Petrović, J. Glamočlija, M. Soković, E. Crespan, G. Maga, Shome S. Bhunia, A.K. Saxena. MedChemComm, 2015, 6, 319-326. (IF = 2.495)
• In vitro metabolism of a novel antithrombotic compound, S002-333, and its enantiomers: quantitative cytochrome P450 phenotyping, metabolic profiling and enzyme kinetic studies. A. Saxena, G.K. Jain, H.H. Siddiqui, Shome S. Bhunia, A.K. Saxena, J.R. Gayen. Xenobiotica. 2013, 44, 295-308. (IF = 2.199)
• Docking studies of novel pyrazinopyridoindoles class of antihistamines with the homology modeled H1-receptor. M. Saxena, Shome S. Bhunia, A.K. Saxena. SAR and QSAR in environmental research. 2012, 23, 11-25. (IF = 2.053)
• Profiling the structural determinants for the selectivity of representative factor-Xa and thrombin inhibitors using combined ligand-based and structure-based approaches. Shome S. Bhunia, K. K. Roy, A.K. Saxena. Journal of chemical information and modeling. 2011, 51, 1966-85. (IF = 4.549)
• CoMFA, CoMSIA, and docking studies on thiolactone-class of potent anti-malarials: identification of essential structural features modulating anti-malarial activity. K.K. Roy, Shome S. Bhunia, A.K. Saxena. Chemical biology & drug design. 2011, 78, 483-93. (IF = 2.548)
• Pharmacophore modelling, molecular docking and virtual screening for EGFR (HER 1) tyrosine kinase inhibitors. A.K. Gupta, Shome S. Bhunia, V.M. Balaramnavar, A.K. Saxena. SAR and QSAR in environmental research. 2011, 22, 239-63. (IF = 2.053)

Book Chapters

• Past, Present, and Future of Antifungal Drug DevelopmentPK Shukla, Pratiksha Singh, Ravindra Kumar Yadav, SmritiPandey, Shome S. Bhunia Springer Berlin Heidelberg.2016, 1-43.
• Development of VEGFR Inhibitors as Antiangiogenic agents. Anil K.Saxena  and Shome S. Bhunia  Medicinal Chemistry Reviews.Vol 51. https://www.acsmedchem.org/
• Integration on Ligand and Structure-Based Approaches in GPCRs. Anil K Saxena, Shome S Bhunia, Mridula Saxena, Topics in Medicinal Chemistry, Springer Berlin Heidelberg, 2017, 1-61.